Recommendations for Practical Use of Metformin, a Central Pharmacological Therapy in Type 2 Diabetes
- 1 January 2022
- journal article
- Published by American Diabetes Association in Clinical Diabetes
- Vol. 40 (1), 97-107
- https://doi.org/10.2337/cd21-0043
Abstract
No abstract availableThis publication has 107 references indexed in Scilit:
- Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes RegisterBMJ Open, 2012
- Glycaemic efficacy of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors as add‐on therapy to metformin in subjects with type 2 diabetes—a review and meta analysisDiabetes, Obesity and Metabolism, 2012
- Clinical Pharmacokinetics of MetforminClinical Pharmacokinetics, 2011
- Lactic Acidosis Induced by MetforminDrug Safety, 2010
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trialThe Lancet, 2010
- Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or HypoglycemiaDiabetes Care, 2008
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesThe New England Journal of Medicine, 2008
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- The Effects of High- and Medium-Dose Metformin Therapy on Cardiovascular Risk Factors in Patients With Type II DiabetesDiabetes Care, 1996
- Worldwide Experience of Metformin as an Effective Glucose-lowering Agent: A Meta-analysisDiabetes/Metabolism Research and Reviews, 1995